A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
OBJECTIVES: Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS). Azacitidine, first-line treatment for the majority of patients with higher-risk MDS, is associated with aggravated thrombocytopenia during the first cycles. Eltrombopag is a nov...
Үндсэн зохиолчид: | Svensson, T, Chowdhury, O, Garelius, H, Lorenz, F, Saft, L, Jacobsen, SE, Hellström-Lindberg, E, Cherif, H |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
2014
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
-н: Francesco D’Alò, зэрэг
Хэвлэсэн: (2021-04-01) -
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)
-н: Sternberg, A, зэрэг
Хэвлэсэн: (2022) -
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
-н: Dickinson, M, зэрэг
Хэвлэсэн: (2018) -
Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
-н: Pedro Marques Ramos, зэрэг
Хэвлэсэн: (2023-08-01) -
Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
-н: Toro Vélez, Esteban, зэрэг
Хэвлэсэн: (2021-07-01)